Markers for Chronic Obstructive Pulmonary Disease (COPD)

Imperial College London

Overview

The primary aim of this study is to exploit a difference between COPD patients, chronic smokers without COPD and healthy non-smoking subjects. This will help to assess the utility of inflammatory and oxidative markers in exhaled air and sputum and to compare them with the lung function, clinical parameters and computerised tomography (CT).

Study Type

OBSERVATIONAL

Conditions

Healthy Non-smokers Current Smokers COPD Patients

Interventions

SpirometryPROCEDURE

Exhaled Nitric Oxide and Carbon MonoxidePROCEDURE

Exhaled Breath CondensatePROCEDURE

Induced SputumPROCEDURE

Eligibility

Sex: ALLMin age: 30 YearsMax age: 75 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: Healthy non-smokers * FEV1 \>80% predicted * FEV1 reversibility of \<10% after inhaled (beta2-agonists Current smokers * FEV1 no less than 80% predicted * FEV1 reversibility of \<10% after inhaled (beta2-agonists * Smoking history of \> 10 pack-years Moderate COPD * FEV1 40-59% predicted * FEV1 reversibility of \<10% after inhaled (beta2-agonists * Smoking history of \> 10 pack-years\*\* Severe COPD * FEV1 \<40% predicted * FEV1 reversibility of \<10% after inhaled (beta2-agonists * Smoking history of \> 10 pack-years Exclusion Criteria: * FEV1 increases by 200 ml and 15% of the baseline value after inhaled (beta2-agonists * Asthma * unstable disease (FEV1 \<35% predicted) and/or current, or within the last 4 weeks, respiratory tract infection.

Locations (1)

Section of Airway Disease, Asthma Lab, Imperial College London, Royal Brompton Hospital

London, United Kingdom

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.